Global Neuroendocrine Carcinoma Drugs Market By Product Type (Somatostatin Analogs, Targeted Therapy) And By End-Users/Application (Hospital, Clinics) Global Market Share, Forecast Data, In-Depth Analysis, And Detailed Overview, and Forecast, 2013 - 2026

  • AMR-986452
  • April 2021
  • Pharmaceuticals
  • 118 Pages

Report Preview

The Neuroendocrine Carcinoma Drugs market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Neuroendocrine Carcinoma Drugs market research report recommends a business strategy for present market participants to strengthen their position in the market.

According to the report, the Neuroendocrine Carcinoma Drugs market size was USD xx million and it is expected to reach USD xx million by the end of 2028, with a CAGR of xx% during 2020-2028. While considering the volume shipments the global Neuroendocrine Carcinoma Drugs market stood at xx (Units/Tons) in 2020 and expected to cross near about xx (units/Tons) by the end of forecast period.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Neuroendocrine Carcinoma Drugs market along with their effects over the forecast period. Similarly, according to the region Neuroendocrine Carcinoma Drugs market research report includes the study of opportunities available in the market situation.

The Neuroendocrine Carcinoma Drugs market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2019
Forecast Period Covered 2019 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Product Type Somatostatin Analogs, Targeted Therapy, Chemotherapy
Applications Hospital, Clinics, Oncology Centres, Ambulatory Surgery Centres
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa
Companies Covered Xiaflex, Novartis AG, Roche, Molecular Insight pharmaceuticals, Callisto Pharmaceuticals

Global Neuroendocrine Carcinoma Drugs Market Segmentation by Regions:
In regional analysis, Neuroendocrine Carcinoma Drugs market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Neuroendocrine Carcinoma Drugs market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Neuroendocrine Carcinoma Drugs Market: Value and Forecast
  • U.S.
  • Canada
 
Europe Region for Neuroendocrine Carcinoma Drugs Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 
Asia Pacific Region for Neuroendocrine Carcinoma Drugs Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 
Latin America Region for Neuroendocrine Carcinoma Drugs Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 
Middle East and Africa for Neuroendocrine Carcinoma Drugs Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa



Global Neuroendocrine Carcinoma Drugs Market Segmentation by Type:
On the basis of product type, global Neuroendocrine Carcinoma Drugs market research report provides the production, revenue, price, and market share and growth rate of each type, primarily split into: Somatostatin Analogs, Targeted Therapy, Chemotherapy

Global Neuroendocrine Carcinoma Drugs Market Segmentation by Applications:
On the basis of the end users/applications, Neuroendocrine Carcinoma Drugs research report analyze the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including: Hospital, Clinics, Oncology Centres, Ambulatory Surgery Centres

Major Key Players for Global Neuroendocrine Carcinoma Drugs Market:
The Neuroendocrine Carcinoma Drugs market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Xiaflex, Novartis AG, Roche, Molecular Insight pharmaceuticals, Callisto Pharmaceuticals

Important Points Covered by Report:
  • To analyze the value of the Neuroendocrine Carcinoma Drugs market, according to the key region.
  • To study the Neuroendocrine Carcinoma Drugs market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Neuroendocrine Carcinoma Drugs market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Neuroendocrine Carcinoma Drugs research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Neuroendocrine Carcinoma Drugs market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Neuroendocrine Carcinoma Drugs market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Neuroendocrine Carcinoma Drugs market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Neuroendocrine Carcinoma Drugs market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Neuroendocrine Carcinoma Drugs market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summary
     2.1. Global Neuroendocrine Carcinoma Drugs Market Snapshot
          2.1.1. Global Neuroendocrine Carcinoma Drugs Market By Type,2019
               2.1.1.1.Somatostatin Analogs
               2.1.1.2.Targeted Therapy
               2.1.1.3.Chemotherapy
          2.1.2. Global Neuroendocrine Carcinoma Drugs Market By Application,2019
               2.1.2.1.Hospital
               2.1.2.2.Clinics
               2.1.2.3.Oncology Centres
               2.1.2.4.Ambulatory Surgery Centres
          2.1.3. Global Neuroendocrine Carcinoma Drugs Market By End-use,2019
          2.1.4. Global Neuroendocrine Carcinoma Drugs Market By Geography,2019

3. Global Neuroendocrine Carcinoma Drugs Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Neuroendocrine Carcinoma Drugs Market Size (US$), By Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Type, 2020
     4.2. Global Neuroendocrine Carcinoma Drugs Market Size (US$), By Type, 2018 – 2028

5. Global Neuroendocrine Carcinoma Drugs Market Size (US$), By Application, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Application, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Application, 2020
     5.2. Global Neuroendocrine Carcinoma Drugs Market Size (US$), By Application, 2018 – 2028

6. Global Neuroendocrine Carcinoma Drugs Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Neuroendocrine Carcinoma Drugs Market Size (US$), By End-use, 2018 – 2028

7. Global Neuroendocrine Carcinoma Drugs Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Neuroendocrine Carcinoma Drugs Market Analysis, 2018 – 2028 
          7.2.1. North America Neuroendocrine Carcinoma Drugs Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Neuroendocrine Carcinoma Drugs Market Size (US$), By Type, 2018 – 2028
          7.2.3. North America Neuroendocrine Carcinoma Drugs Market Size (US$), By Application, 2018 – 2028
          7.2.4. North America Neuroendocrine Carcinoma Drugs Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Neuroendocrine Carcinoma Drugs Market Analysis, 2018 – 2028 
          7.3.1.  Europe Neuroendocrine Carcinoma Drugs Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Neuroendocrine Carcinoma Drugs Market Size (US$), By Type, 2018 – 2028
          7.3.3. Europe Neuroendocrine Carcinoma Drugs Market Size (US$), By Application, 2018 – 2028
          7.3.4. Europe Neuroendocrine Carcinoma Drugs Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Neuroendocrine Carcinoma Drugs Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Neuroendocrine Carcinoma Drugs Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Neuroendocrine Carcinoma Drugs Market Size (US$), By Type, 2018 – 2028
          7.4.3. Asia Pacific Neuroendocrine Carcinoma Drugs Market Size (US$), By Application, 2018 – 2028
          7.4.4. Asia Pacific Neuroendocrine Carcinoma Drugs Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Neuroendocrine Carcinoma Drugs Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Neuroendocrine Carcinoma Drugs Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Neuroendocrine Carcinoma Drugs Market Size (US$), By Type, 2018 – 2028
          7.5.3. Latin America Neuroendocrine Carcinoma Drugs Market Size (US$), By Application, 2018 – 2028
          7.5.4. Latin America Neuroendocrine Carcinoma Drugs Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Neuroendocrine Carcinoma Drugs Market Analysis, 2018 – 2028 
          7.6.1.  MEA Neuroendocrine Carcinoma Drugs Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Neuroendocrine Carcinoma Drugs Market Size (US$), By Type, 2018 – 2028
          7.6.3. MEA Neuroendocrine Carcinoma Drugs Market Size (US$), By Application, 2018 – 2028
          7.6.4. MEA Neuroendocrine Carcinoma Drugs Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Neuroendocrine Carcinoma Drugs Providers
        8.4.1 Xiaflex
                8.1.1 Business Description
                8.1.2 Xiaflex Geographic Operations
                8.1.3 Xiaflex Financial Information
                8.1.4 Xiaflex Product Positions/Portfolio
                8.1.5 Xiaflex Key Developments
        8.4.2 Novartis AG
                8.2.1 Business Description
                8.2.2 Novartis AG Geographic Operations
                8.2.3 Novartis AG Financial Information
                8.2.4 Novartis AG Product Positions/Portfolio
                8.2.5 Novartis AG Key Developments
        8.4.3 Roche
                8.3.1 Business Description
                8.3.2 Roche Geographic Operations
                8.3.3 Roche Financial Information
                8.3.4 Roche Product Positions/Portfolio
                8.3.5 Roche Key Developments
        8.4.4 Molecular Insight pharmaceuticals
                8.4.1 Business Description
                8.4.2 Molecular Insight pharmaceuticals Geographic Operations
                8.4.3 Molecular Insight pharmaceuticals Financial Information
                8.4.4 Molecular Insight pharmaceuticals Product Positions/Portfolio
                8.4.5 Molecular Insight pharmaceuticals Key Developments
        8.4.5 Callisto Pharmaceuticals
                8.5.1 Business Description
                8.5.2 Callisto Pharmaceuticals Geographic Operations
                8.5.3 Callisto Pharmaceuticals Financial Information
                8.5.4 Callisto Pharmaceuticals Product Positions/Portfolio
                8.5.5 Callisto Pharmaceuticals Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Neuroendocrine Carcinoma Drugs Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Neuroendocrine Carcinoma Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Neuroendocrine Carcinoma Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Neuroendocrine Carcinoma Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Neuroendocrine Carcinoma Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Neuroendocrine Carcinoma Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Neuroendocrine Carcinoma Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Neuroendocrine Carcinoma Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Neuroendocrine Carcinoma Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Neuroendocrine Carcinoma Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Neuroendocrine Carcinoma Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Neuroendocrine Carcinoma Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Neuroendocrine Carcinoma Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Neuroendocrine Carcinoma Drugs Market Revenue, By Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Neuroendocrine Carcinoma Drugs Market Revenue, By Application, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Neuroendocrine Carcinoma Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Neuroendocrine Carcinoma Drugs: Market Segmentation 
FIG. 2 Global Neuroendocrine Carcinoma Drugs Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Neuroendocrine Carcinoma Drugs Market, By Type, 2019 (US$ Mn) 
FIG. 5 Global Neuroendocrine Carcinoma Drugs Market, By Application, 2019 (US$ Mn) 
FIG. 6 Global Neuroendocrine Carcinoma Drugs Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Neuroendocrine Carcinoma Drugs Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Neuroendocrine Carcinoma Drugs Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Neuroendocrine Carcinoma Drugs Providers, 2019
FIG. 11 Global Neuroendocrine Carcinoma Drugs Market Revenue Contribution, By Type, 2019 & 2028 (Value %) 
FIG. 12 Global Neuroendocrine Carcinoma Drugs Market Revenue Contribution, By Application, 2019 & 2028 (Value %) 
FIG. 13 Global Neuroendocrine Carcinoma Drugs Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Neuroendocrine Carcinoma Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Neuroendocrine Carcinoma Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Neuroendocrine Carcinoma Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Neuroendocrine Carcinoma Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Neuroendocrine Carcinoma Drugs Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Neuroendocrine Carcinoma Drugs market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Neuroendocrine Carcinoma Drugs Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Neuroendocrine Carcinoma Drugs Market Value, By Segment1, 2018 – 2028
TABLE  North America Neuroendocrine Carcinoma Drugs Market Value, By Segment2, 2018 – 2028
TABLE  North America Neuroendocrine Carcinoma Drugs Market Value, By Country, 2018 – 2028
TABLE  Europe Neuroendocrine Carcinoma Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Europe Neuroendocrine Carcinoma Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Europe Neuroendocrine Carcinoma Drugs Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Neuroendocrine Carcinoma Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Neuroendocrine Carcinoma Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Neuroendocrine Carcinoma Drugs Market Value, By Country, 2018 – 2028
TABLE  Latin America Neuroendocrine Carcinoma Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Neuroendocrine Carcinoma Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Neuroendocrine Carcinoma Drugs Market Value, By Country, 2018 – 2028
TABLE  MEA Neuroendocrine Carcinoma Drugs Market Value, By Segment1, 2018 – 2028
TABLE  MEA Neuroendocrine Carcinoma Drugs Market Value, By Segment2, 2018 – 2028
TABLE  MEA Neuroendocrine Carcinoma Drugs Market Value, By Country, 2018 – 2028
TABLE  Xiaflex: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Novartis AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Roche: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Molecular Insight pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Callisto Pharmaceuticals: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Neuroendocrine Carcinoma Drugs Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Neuroendocrine Carcinoma Drugs Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Neuroendocrine Carcinoma Drugs Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Neuroendocrine Carcinoma Drugs Market, By Geography, 2019 (US$ Mn)
FIG.  Global Neuroendocrine Carcinoma Drugs Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Neuroendocrine Carcinoma Drugs Providers, 2016
FIG.  Global Neuroendocrine Carcinoma Drugs Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Somatostatin Analogs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Targeted Therapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Chemotherapy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Neuroendocrine Carcinoma Drugs Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Hospital Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Clinics Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Oncology Centres Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Ambulatory Surgery Centres Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Neuroendocrine Carcinoma Drugs Market Value, 2018 – 2028, (US$ Mn)